- Home
- PLUR vs ECOR Comparison
PLUR vs ECOR Comparison
Compare PLUR & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUR
- ECOR
- Stock Information
- Founded
- PLUR 2001
- ECOR 2005
- Country
- PLUR Israel
- ECOR United States
- Employees
- PLUR N/A
- ECOR N/A
- Industry
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PLUR Health Care
- ECOR Health Care
- Exchange
- PLUR Nasdaq
- ECOR Nasdaq
- Market Cap
- PLUR 36.9M
- ECOR 40.0M
- IPO Year
- PLUR N/A
- ECOR 2018
- Fundamental
- Price
- PLUR $3.91
- ECOR $4.90
- Analyst Decision
- PLUR Strong Buy
- ECOR Strong Buy
- Analyst Count
- PLUR 1
- ECOR 2
- Target Price
- PLUR $12.00
- ECOR $25.50
- AVG Volume (30 Days)
- PLUR 10.5K
- ECOR 45.8K
- Earning Date
- PLUR 11-11-2025
- ECOR 11-05-2025
- Dividend Yield
- PLUR N/A
- ECOR N/A
- EPS Growth
- PLUR N/A
- ECOR N/A
- EPS
- PLUR N/A
- ECOR N/A
- Revenue
- PLUR $1,336,000.00
- ECOR $27,700,000.00
- Revenue This Year
- PLUR $97.38
- ECOR $23.74
- Revenue Next Year
- PLUR $293.97
- ECOR $42.02
- P/E Ratio
- PLUR N/A
- ECOR N/A
- Revenue Growth
- PLUR 309.82
- ECOR 30.16
- 52 Week Low
- PLUR $3.33
- ECOR $4.16
- 52 Week High
- PLUR $7.13
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- PLUR 41.69
- ECOR 46.12
- Support Level
- PLUR $3.60
- ECOR $4.86
- Resistance Level
- PLUR $4.09
- ECOR $5.19
- Average True Range (ATR)
- PLUR 0.18
- ECOR 0.23
- MACD
- PLUR -0.02
- ECOR 0.00
- Stochastic Oscillator
- PLUR 30.69
- ECOR 34.40
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.